BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. Journal of Hepatology 2005;42:210-7. [DOI: 10.1016/j.jhep.2004.10.020] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Vinken M, Henkens T, Snykers S, Lukaszuk A, Tourwé D, Rogiers V, Vanhaecke T. The novel histone deacetylase inhibitor 4-Me2N-BAVAH differentially affects cell junctions between primary hepatocytes. Toxicology. 2007;236:92-102. [PMID: 17482745 DOI: 10.1016/j.tox.2007.04.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell 2014;5:673-91. [PMID: 24916440 DOI: 10.1007/s13238-014-0065-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 10.0] [Reference Citation Analysis]
3 Mohammadi A, Sharifi A, Pourpaknia R, Mohammadian S, Sahebkar A. Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation. Critical Reviews in Oncology/Hematology 2018;128:1-18. [DOI: 10.1016/j.critrevonc.2018.05.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
4 Chateauvieux S, Eifes S, Morceau F, Grigorakaki C, Schnekenburger M, Henry E, Dicato M, Diederich M. Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochemical Pharmacology 2011;81:498-509. [DOI: 10.1016/j.bcp.2010.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
5 Kwiecińska P, Taubøll E, Gregoraszczuk EŁ. Comparison of the effects of valproic acid and levetiracetam on apoptosis in the human ovarian cancer cell line OVCAR-3. Pharmacological Reports 2012;64:603-14. [DOI: 10.1016/s1734-1140(12)70856-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
6 Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci 2014;71:3885-901. [PMID: 24898083 DOI: 10.1007/s00018-014-1656-6] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 14.0] [Reference Citation Analysis]
7 Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol. 2012;30:3361-3367. [PMID: 22915658 DOI: 10.1200/jco.2011.41.2395] [Cited by in Crossref: 127] [Cited by in F6Publishing: 73] [Article Influence: 12.7] [Reference Citation Analysis]
8 Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. J Hepatol 2016;65:280-8. [PMID: 26952006 DOI: 10.1016/j.jhep.2016.02.043] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
9 Soukupova J, Bertran E, Peñuelas-Haro I, Urdiroz-Urricelqui U, Borgman M, Kohlhof H, Fabregat I. Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis. Oncotarget 2017;8:110367-79. [PMID: 29299154 DOI: 10.18632/oncotarget.22775] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
10 Tong A, Zhang H, Li Z, Gou L, Wang Z, Wei H, Tang M, Liang S, Chen L, Huang C, Wei Y. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 2008;61:791-802. [DOI: 10.1007/s00280-007-0536-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
11 Liu Y, Wang Z, Wang J, Lam W, Kwong S, Li F, Friedman SL, Zhou S, Ren Q, Xu Z, Wang X, Ji L, Tang S, Zhang H, Lui EL, Ye T. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling. Liver Int 2013;33:504-15. [PMID: 23279742 DOI: 10.1111/liv.12034] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
12 Fraczek J, Vanhaecke T, Rogiers V. Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 2013;9:441-57. [PMID: 23286281 DOI: 10.1517/17425255.2013.754011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
13 Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, Zhang L, Klune JR, Zlotnicki J, Billiar T, Tsung A. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem. 2010;285:39888-39897. [PMID: 20937823 DOI: 10.1074/jbc.m110.128348] [Cited by in Crossref: 160] [Cited by in F6Publishing: 100] [Article Influence: 13.3] [Reference Citation Analysis]
14 Venturelli S, Berger A, Böcker A, Busch C, Weiland T, Noor S, Leischner C, Schleicher S, Mayer M, Weiss TS, Bischoff SC, Lauer UM, Bitzer M. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One 2013;8:e73097. [PMID: 24023672 DOI: 10.1371/journal.pone.0073097] [Cited by in Crossref: 72] [Cited by in F6Publishing: 84] [Article Influence: 8.0] [Reference Citation Analysis]
15 Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park WS, Lee JY, Nam SW. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 2011;6:e28103. [PMID: 22132221 DOI: 10.1371/journal.pone.0028103] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
16 Pelascini LP, Maggio I, Liu J, Holkers M, Cathomen T, Gonçalves MA. Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases. Hum Gene Ther Methods 2013;24:399-411. [PMID: 24059449 DOI: 10.1089/hgtb.2013.107] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
17 Chou YW, Lin FF, Muniyan S, Lin FC, Chen CS, Wang J, Huang CC, Lin MF. Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression. Cell Biosci 2015;5:38. [PMID: 26185616 DOI: 10.1186/s13578-015-0033-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
18 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
19 Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 2009;13:826-52. [PMID: 19175682 DOI: 10.1111/j.1582-4934.2008.00571.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
20 Zhang Y, Yu G, Wang D, Hu Y, Lei W. ERK1/2 activation plays important roles in the opposite effects of Trichostatin A in non-cancer and cancer cells. Toxicon 2011;57:932-7. [DOI: 10.1016/j.toxicon.2011.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
21 Catalioto R, Maggi CA, Giuliani S. Chemically distinct HDAC inhibitors prevent adipose conversion of subcutaneous human white preadipocytes at an early stage of the differentiation program. Experimental Cell Research 2009;315:3267-80. [DOI: 10.1016/j.yexcr.2009.09.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
22 Conde de la Rosa L, Schoemaker MH, Vrenken TE, Buist-Homan M, Havinga R, Jansen PL, Moshage H. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. J Hepatol. 2006;44:918-929. [PMID: 16310883 DOI: 10.1016/j.jhep.2005.07.034] [Cited by in Crossref: 146] [Cited by in F6Publishing: 144] [Article Influence: 8.6] [Reference Citation Analysis]
23 Liu KY, Wang LT, Hsu SH. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E8. [PMID: 29301348 DOI: 10.3390/cancers10010008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
24 Wilson CL, Mann DA, Borthwick LA. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev 2017;121:124-32. [PMID: 29079534 DOI: 10.1016/j.addr.2017.10.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
25 Kouraklis G, Misiakos EP, Theocharis S. Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment. Targ Oncol 2006;1:34-41. [DOI: 10.1007/s11523-005-0007-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell. 2014;5:673-691. [PMID: 24916440 DOI: 10.1007/s13238- 014-0065-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 2010;235:32-9. [PMID: 20404016 DOI: 10.1258/ebm.2009.009252] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
28 Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, Moriwaki H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009;285:210-7. [PMID: 19520494 DOI: 10.1016/j.canlet.2009.05.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
29 Gonzales ER, Chen H, Munuve RM, Mehrani T, Nadel A, Koustova E. Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock. J Trauma. 2008;65:554-565. [PMID: 18784568 DOI: 10.1097/TA.0b013e31818233ef] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
30 Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008;27:1767-78. [DOI: 10.1038/sj.onc.1210820] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
31 Shein NA, Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol Med 2011;17:448-56. [PMID: 21274503 DOI: 10.2119/molmed.2011.00038] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
32 Yoo YG, Na TY, Seo HW, Seong JK, Park CK, Shin YK, Lee MO. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene 2008;27:3405-13. [PMID: 18264140 DOI: 10.1038/sj.onc.1211000] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 7.8] [Reference Citation Analysis]
33 Wang YG, Xu L, Wang T, Wei J, Meng WY, Wang N, Shi M. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol 2015; 21(27): 8326-8339 [PMID: 26217084 DOI: 10.3748/wjg.v21.i27.8326] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
34 Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R, Tesoriere G. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007;12:1327-38. [PMID: 17351739 DOI: 10.1007/s10495-007-0063-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
35 Beck A, Eberherr C, Hagemann M, Cairo S, Häberle B, Vokuhl C, von Schweinitz D, Kappler R. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. Cancer Biol Ther 2016;17:1168-76. [PMID: 27635950 DOI: 10.1080/15384047.2016.1235664] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
36 Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach. World J Gastroenterol 2007; 13(35): 4761-4770 [PMID: 17729398 DOI: 10.3748/wjg.v13.i35.4761] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
37 Carta S, Tassi S, Semino C, Fossati G, Mascagni P, Dinarello CA, Rubartelli A. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood. 2006;108:1618-1626. [PMID: 16684958 DOI: 10.1182/blood-2006-03-014126] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 6.6] [Reference Citation Analysis]
38 Zhang Y, Feng J, Liu C, Zhang L, Jiao J, Fang H, Su L, Zhang X, Zhang J, Li M, Wang B, Xu W. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. Bioorganic & Medicinal Chemistry 2010;18:1761-72. [DOI: 10.1016/j.bmc.2010.01.060] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
39 Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P, Rambaldi A, Neri A, Introna M, Lombardi L, Golay J. Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 2010;95:260-9. [PMID: 19713220 DOI: 10.3324/haematol.2009.012088] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
40 Almeida B, Silva A, Mesquita A, Sampaio-Marques B, Rodrigues F, Ludovico P. Drug-induced apoptosis in yeast. Biochim Biophys Acta 2008;1783:1436-48. [PMID: 18252203 DOI: 10.1016/j.bbamcr.2008.01.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
41 Dong XJ, Zhang GR, Zhou QJ, Pan RL, Chen Y, Xiang LX, Shao JZ. Direct hepatic differentiation of mouse embryonic stem cells induced by valproic acid and cytokines. World J Gastroenterol 2009; 15(41): 5165-5175 [PMID: 19891015 DOI: 10.3748/wjg.15.5165] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
42 Mosley AJ, Meekings KN, Mccarthy C, Shepherd D, Cerundolo V, Mazitschek R, Tanaka Y, Taylor GP, Bangham CR. Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection. Blood 2006;108:3801-7. [DOI: 10.1182/blood-2006-03-013235] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
43 Liu S, Wang N, Yao H, Jiang N, Lu X. Preparation and identification of monoclonal antibody against human hepatocellular carcinoma with a novel immunization. Hybridoma (Larchmt). 2009;28:43-50. [PMID: 19239369 DOI: 10.1089/hyb.2008.0060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J, Zheng SS. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 2010;5:e14460. [PMID: 21206745 DOI: 10.1371/journal.pone.0014460] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
45 Ganai SA. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies. J Chemother 2016;28:247-54. [PMID: 27121910 DOI: 10.1080/1120009X.2016.1145375] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
46 Riester D, Hildmann C, Schwienhorst A. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbiol Biotechnol 2007;75:499-514. [PMID: 17377788 DOI: 10.1007/s00253-007-0912-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
47 Baskin–bey ES, Gores GJ. Caspase-8, Death-Receptor Signaling, and Hepatocarcinogenesis: The Fas and the Furious. Gastroenterology 2005;129:1790-2. [DOI: 10.1053/j.gastro.2005.09.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
48 Trécul A, Morceau F, Gaigneaux A, Schnekenburger M, Dicato M, Diederich M. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochemical Pharmacology 2014;92:299-311. [DOI: 10.1016/j.bcp.2014.07.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
49 Friedrich M, Gerbeth L, Gerling M, Rosenthal R, Steiger K, Weidinger C, Keye J, Wu H, Schmidt F, Weichert W, Siegmund B, Glauben R. HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFβ1 signalling in inflammation. Mucosal Immunol 2019;12:656-67. [PMID: 30674988 DOI: 10.1038/s41385-019-0135-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
50 Zhou H, Jiang S, Chen J, Su SB. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. Can J Physiol Pharmacol 2014;92:879-85. [PMID: 25272091 DOI: 10.1139/cjpp-2014-0117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
51 Larsen L, Tonnesen M, Ronn SG, Størling J, Jørgensen S, Mascagni P, Dinarello CA, Billestrup N, Mandrup-Poulsen T. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia. 2007;50:779-789. [PMID: 17265033 DOI: 10.1007/s00125-006-0562-3] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 6.1] [Reference Citation Analysis]
52 Joanna F, van Grunsven LA, Mathieu V, Sarah S, Sarah D, Karin V, Tamara V, Vera R. Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. J Cell Mol Med 2009;13:2990-3005. [PMID: 19583816 DOI: 10.1111/j.1582-4934.2009.00831.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
53 Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int 2017;11:45-53. [PMID: 27271356 DOI: 10.1007/s12072-016-9743-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
54 Su H, Yu L, Nebbioso A, Carafa V, Chen Y, Altucci L, You Q. Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. Bioorganic & Medicinal Chemistry Letters 2009;19:6284-8. [DOI: 10.1016/j.bmcl.2009.09.100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
55 Xu W, Liu H, Liu ZG, Wang HS, Zhang F, Wang H, Zhang J, Chen JJ, Huang HJ, Tan Y, Cao MT, Du J, Zhang QG, Jiang GM. Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells. Cancer Lett 2018;420:1-13. [PMID: 29410023 DOI: 10.1016/j.canlet.2018.01.068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
56 Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007;46:1119-30. [PMID: 17654699 DOI: 10.1002/hep.21804] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
57 Venturelli S, Armeanu S, Pathil A, Hsieh C, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007;109:2132-41. [DOI: 10.1002/cncr.22652] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
58 Ouyang D, Zhang Y, Xu L, Li J, Zha Q, He X. Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. Acta Biochim Biophys Sin (Shanghai) 2011;43:487-95. [PMID: 21628505 DOI: 10.1093/abbs/gmr032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
59 Freese K, Seitz T, Dietrich P, Lee SML, Thasler WE, Bosserhoff A, Hellerbrand C. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro. Cancers (Basel) 2019;11:E1587. [PMID: 31635225 DOI: 10.3390/cancers11101587] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
60 Delgado FG, Cárdenas P, Castellanos JE. Valproic Acid Downregulates Cytokine Expression in Human Macrophages Infected with Dengue Virus. Diseases 2018;6:E59. [PMID: 29986388 DOI: 10.3390/diseases6030059] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
61 Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics. Gut 2016;65:1895-905. [PMID: 27624887 DOI: 10.1136/gutjnl-2015-311292] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 14.5] [Reference Citation Analysis]
62 Angeletti F, Fossati G, Pattarozzi A, Würth R, Solari A, Daga A, Masiello I, Barbieri F, Florio T, Comincini S. Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells. Front Mol Neurosci 2016;9:107. [PMID: 27833530 DOI: 10.3389/fnmol.2016.00107] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
63 Wahid B, Ali A, Rafique S, Idrees M. New Insights into the Epigenetics of Hepatocellular Carcinoma. Biomed Res Int 2017;2017:1609575. [PMID: 28401148 DOI: 10.1155/2017/1609575] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
64 Shein NA, Grigoriadis N, Alexandrovich AG, Simeonidou C, Lourbopoulos A, Polyzoidou E, Trembovler V, Mascagni P, Dinarello CA, Shohami E. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J 2009;23:4266-75. [PMID: 19723705 DOI: 10.1096/fj.09-134700] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
65 Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 2006;130:2130-44. [PMID: 16762634 DOI: 10.1053/j.gastro.2006.02.056] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
66 Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21:1892-1900. [PMID: 17637810 DOI: 10.1038/sj.leu.2404860] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 5.4] [Reference Citation Analysis]
67 Snykers S, Henkens T, De Rop E, Vinken M, Fraczek J, De Kock J, De Prins E, Geerts A, Rogiers V, Vanhaecke T. Role of epigenetics in liver-specific gene transcription, hepatocyte differentiation and stem cell reprogrammation. Journal of Hepatology 2009;51:187-211. [DOI: 10.1016/j.jhep.2009.03.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
68 Zhao LM, Zhang JH. Histone Deacetylase Inhibitors in Tumor Immunotherapy. Curr Med Chem 2019;26:2990-3008. [PMID: 28762309 DOI: 10.2174/0929867324666170801102124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
69 Lu P, Yan M, He L, Li J, Ji Y, Ji J. Crosstalk between Epigenetic Modulations in Valproic Acid Deactivated Hepatic Stellate Cells: An Integrated Protein and miRNA Profiling Study. Int J Biol Sci. 2019;15:93-104. [PMID: 30662350 DOI: 10.7150/ijbs.28642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006;43:425-34. [PMID: 16583461 DOI: 10.1002/hep.21054] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 5.6] [Reference Citation Analysis]